Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty 100 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Reddy's Laboratories received the Establishment Inspection Report (EIR) from the USFDA on August 7, 2025, following the earlier GMP inspection at its API manufacturing facility (CTO 5) in Miryalaguda, Telangana. The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)' — the most favorable of the three FDA classifications — and officially closed the inspection under 21 CFR 20.64(d)(3). VAI means the FDA identified some observations but considers them manageable through voluntary corrective steps by the company, with no mandatory regulatory action required. The closure removes an overhang related to this facility's compliance status.
Positive for shareholders — the clean closure of the USFDA inspection with a VAI classification removes regulatory uncertainty around the Miryalaguda facility and supports uninterrupted API production and exports to the US market, which is a key revenue driver for the company.